Schrader Sarah M, Vaubourgeix Julien, Nathan Carl
Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY 10065, USA.
MRC Centre for Molecular Bacteriology and Infection, Imperial College London, London SW7 2AZ, UK.
Sci Transl Med. 2020 Jun 24;12(549). doi: 10.1126/scitranslmed.aaz6992.
Insufficient development of new antibiotics and the rising resistance of bacteria to those that we have are putting the world at risk of losing the most widely curative class of medicines currently available. Preventing deaths from antimicrobial resistance (AMR) will require exploiting emerging knowledge not only about genetic AMR conferred by horizontal gene transfer or de novo mutations but also about phenotypic AMR, which lacks a stably heritable basis. This Review summarizes recent advances and continuing limitations in our understanding of AMR and suggests approaches for combating its clinical consequences, including identification of previously unexploited bacterial targets, new antimicrobial compounds, and improved combination drug regimens.
新抗生素研发不足,且细菌对现有抗生素的耐药性不断增强,这使世界面临失去当前最广泛使用的具有治愈功效药物类别的风险。预防抗菌药物耐药性(AMR)导致的死亡,不仅需要利用有关水平基因转移或从头突变赋予的遗传性AMR的新知识,还需要利用有关缺乏稳定遗传基础的表型AMR的知识。本综述总结了我们对AMR理解的最新进展和持续存在的局限性,并提出了应对其临床后果的方法,包括识别以前未被开发的细菌靶点、新型抗菌化合物以及改进联合用药方案。